Published in Hematology Week, September 4th, 2006
Investigators working in Israel aimed to "assess bleeding complications among patients undergoing percutaneous coronary intervention (PCI) and receiving triple therapy of warfarin, aspirin, and a thienopyridine."
A. Porter and colleagues at Rabin Medical Center in Petah-Tikva wrote, "Triple therapy of warfarin, aspirin, and a thienopyridine is strongly discouraged, given the potential risk of bleeding complications. Post-PCI patients receiving triple therapy thereafter underwent assessment for bleeding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.